Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.73 |
| ▸ | HTR1A | P08908 | 10/20 | 0.67 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.66 |
| ▸ | DRD2 | P14416 | 3/20 | 0.65 |
| ▸ | DRD4 | P21917 | 3/20 | 0.62 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.59 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.59 |
| ▸ | HRH2 | P25021 | 1/20 | 0.59 |
| ▸ | HTR1B | P28222 | 1/20 | 0.59 |
| ▸ | HTR2A | P28223 | 1/20 | 0.59 |
| ▸ | HTR7 | P34969 | 1/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.59 |
| ▸ | HRH1 | P35367 | 1/20 | 0.59 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.59 |
| ▸ | HTR2B | P41595 | 1/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3212431 | 0.99 | KCNH2 (0.71) | KCNH2HTR1ACACNA1GDRD2DRD4 | |
| SCHEMBL27895258 | 0.96 | KCNH2 (0.76) | KCNH2HTR1ACACNA1GDRD2DRD4 | |
| SCHEMBL3196635 | 0.88 | KCNH2 (0.55) | KCNH2HTR1ACACNA1GDRD2DRD4 | |
| Hydrochloric Acid SCHEMBL3194757 | 0.87 | KCNH2 (0.53) | KCNH2HTR1ACACNA1GDRD2DRD4 | |
| SCHEMBL3186218 | 0.85 | HSD17B10 (0.70) | HTR1ADRD2DRD4ADRA2AADRA2C | |
| SCHEMBL4395587 | 0.85 | ALDH1A1 (0.63) | KCNH2HTR1ADRD2DRD4MAPT | |
| SCHEMBL4525293 | 0.85 | KCNH2 (1.00) | KCNH2HTR1ADRD2DRD4ADRA2A | |
| SCHEMBL2114590 | 0.84 | KCNH2 (0.68) | KCNH2HTR1ACACNA1GDRD2DRD4 | |
| SCHEMBL3198969 | 0.84 | KCNH2 (0.72) | KCNH2HTR1ADRD2DRD4HTR2A | |
| Hydrochloric Acid SCHEMBL3199211 | 0.84 | HSD17B10 (0.68) | HTR1ADRD2DRD4HTR2AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029682-A1 | NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME | PIERRE FABRE MEDICAMENT (FR) | 2010-02-04 | — | — | US | claimed |
| US-20090238761-A1 | Novel Aryl Piperazine Derivatives With Medical Utility | UNIVERSITA DEGLI STUDI DI SIENA (IT) | 2009-09-24 | — | — | US | claimed |
| EP-2057138-A1 | NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME | Pierre Fabre Medicament (FR) | 2009-05-13 | — | — | EP | claimed |
| WO-2008009741-A1 | NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME | PIERRE FABRE MEDICAMENT (FR) | 2008-01-24 | — | — | WO | claimed |
| US-20100029682-A1 | NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME | PIERRE FABRE MEDICAMENT (FR) | 2010-02-04 | — | — | US | disclosed |
| US-20090238761-A1 | Novel Aryl Piperazine Derivatives With Medical Utility | UNIVERSITA DEGLI STUDI DI SIENA (IT) | 2009-09-24 | — | — | US | disclosed |
| EP-2057138-A1 | NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME | Pierre Fabre Medicament (FR) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008009741-A1 | NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME | PIERRE FABRE MEDICAMENT (FR) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029682-A1 | NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME | DRD3, CHRNA3, CHRM3 | KCNH2 1015/4885HTR1A 66/4885CACNA1G 245/4885 |
| US-20090238761-A1 | Novel Aryl Piperazine Derivatives With Medical Utility | HTR2C, HTR2A, DRD2 | KCNH2 769/4885HTR1A 15/4885CACNA1G 1158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.